« Back to whitepapers archive
Whitepapers
Europe's stellar decade of prostate cancer innovation
By: Rob Johnson
Sep
2011
After 30 years of no new drug approvals, since 2004 five new drugs have demonstrated substantial evidence of efficacy in Phase III trials. Despite a quadrupling of NCI spending on prostate cancer from 1997 to 2008, it is striking that 80% of these new drugs were invented in Europe.
Download the full whitepaper PDF below: